FDA grants priority review for Lucentis for myopic CNV

The FDA accepted a supplemental biologics license application and granted priority review for Lucentis for the treatment of myopic choroidal neovascularization, according to a Genentech press release.The application is based on the 12-month, randomized, double-masked, multicenter phase 3 RADIANCE study, in which Lucentis (ranibizumab) provided “superior visual acuity gains” in patients with myopic CNV compared with verteporfin photodynamic therapy, the release said.